News >

Phase III Data Show Benefit With Abiraterone in Castration-Sensitive Prostate Cancer

Danielle Bucco
Published: Wednesday, Oct 04, 2017

Tian Zhang, MD

Tian Zhang, MD
Metastatic castration-sensitive prostate cancer is an aggressive tumor type that continues to be investigated, experts say.

on Genitourinary Cancers, Zhang, an assistant professor of medicine, Department of Medicine, Duke University School of Medicine, Duke Cancer Institute, discussed emerging results for patients with metastatic castration-sensitive prostate cancer.

OncLive: Please provide an overview of your presentation.

Zhang: We talked about metastatic castration-sensitive prostate cancer, which is a very aggressive tumor type when it is presented de novo. I also discussed the novel treatments for these patients. We’ve had docetaxel for a good number of years. At the 2017 ASCO Annual Meeting, there were presentations of both the LATITUDE data as well as the STAMPEDE analysis of abiraterone versus ADT. I gave overviews of both LATITUDE and STAMPEDE studies investigating abiraterone acetate. 
... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Community Practice Connections™: 2nd Annual International Congress on Oncology Pathology™Aug 31, 20191.5
Clinical Practice Connections™: New York Advanced Practice CollaborativeNov 15, 20191.25
Publication Bottom Border
Border Publication
x